Rigel Pharmaceuticals, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company expected to report total revenue of approximately $51.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 USD | -1.01% | -2.84% | -34.48% |
May. 07 | Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.48% | 167M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022